Signaling Gateway - 29 January 2010
http://links.ealert.nature.com/ctt?kn=36&m=34590207&r=MTc2ODc4NDI0MAS2&b=2&j=NjYzMTE5NjgS1&mt=1&rt=0
*********************************************************************
Signaling Update is a one-stop online resource designed to keep you
in touch with the latest and most exciting research in cell
signaling. New content is uploaded every Friday.
http://links.ealert.nature.com/ctt?kn=12&m=34590207&r=MTc2ODc4NDI0MAS2&b=2&j=NjYzMTE5NjgS1&mt=1&rt=0
*********************************************************************
In Signaling Update this week:
------------------------
Featured Article
------------------------
CELL SIGNALING: IT'S GOOD TO TALK
Cell-specific signaling networks during the interaction between
cells.
Original research paper: Science 326, 1502-1509 (2009)
http://links.ealert.nature.com/ctt?kn=24&m=34590207&r=MTc2ODc4NDI0MAS2&b=2&j=NjYzMTE5NjgS1&mt=1&rt=0
------------------------
Molecule Pages
------------------------
RECOVERIN
http://links.ealert.nature.com/ctt?kn=7&m=34590207&r=MTc2ODc4NDI0MAS2&b=2&j=NjYzMTE5NjgS1&mt=1&rt=0
Recoverin, initially named p26, belongs to the neuronal calcium
sensor protein family and is a Ca2+-binding protein with a
predominantly retinal localization. Recoverin serves as a
Ca2+-dependent regulator of G-protein-coupled receptor kinase 1
(GRK-1; rhodopsin kinase), which is the enzyme that catalyzes
phosphorylation and thus desensitization of the visual receptor
rhodopsin. The aberrant expression of recoverin in malignant tumors
can cause an autoimmune response in some cancer patients that is
followed by the development of cancer-associated retinopathy.
Also published this week:
TRB2
http://links.ealert.nature.com/ctt?kn=6&m=34590207&r=MTc2ODc4NDI0MAS2&b=2&j=NjYzMTE5NjgS1&mt=1&rt=0
MPS1
http://links.ealert.nature.com/ctt?kn=10&m=34590207&r=MTc2ODc4NDI0MAS2&b=2&j=NjYzMTE5NjgS1&mt=1&rt=0
search the molecule pages
http://links.ealert.nature.com/ctt?kn=8&m=34590207&r=MTc2ODc4NDI0MAS2&b=2&j=NjYzMTE5NjgS1&mt=1&rt=0
-------------------
Selected Updates
-------------------
NEURODEGENERATIVE DISEASE: SYNERGISTIC DESTRUCTION
Amyloid–beta and tau synergistically impair mitochondrial function in
AD mice.
Original research paper: Proc. Natl Acad. Sci. USA 106,
20057-20062 (2009)
http://links.ealert.nature.com/ctt?kn=2&m=34590207&r=MTc2ODc4NDI0MAS2&b=2&j=NjYzMTE5NjgS1&mt=1&rt=0
PROTEIN DEGRADATION: STEP BY STEP
Ubiquitin chains are built by sequential transfer of single
molecules.
Original research paper: Cell 139, 957-968 (2009)
http://links.ealert.nature.com/ctt?kn=1&m=34590207&r=MTc2ODc4NDI0MAS2&b=2&j=NjYzMTE5NjgS1&mt=1&rt=0
INNATE IMMUNITY: MICRORNAS LIMIT LPS LETHALITY
Pro-inflammatory protein PDCD4 targeted by microRNA tempers LPS
toxicity.
Original research paper: Nature Immunol. 11, 141-147 (2009)
http://links.ealert.nature.com/ctt?kn=5&m=34590207&r=MTc2ODc4NDI0MAS2&b=2&j=NjYzMTE5NjgS1&mt=1&rt=0
More Updates:
http://links.ealert.nature.com/ctt?kn=17&m=34590207&r=MTc2ODc4NDI0MAS2&b=2&j=NjYzMTE5NjgS1&mt=1&rt=0
------------------------
Research Library
------------------------
http://links.ealert.nature.com/ctt?kn=16&m=34590207&r=MTc2ODc4NDI0MAS2&b=2&j=NjYzMTE5NjgS1&mt=1&rt=0
THE TRANSCRIPTIONAL NETWORK FOR MESENCHYMAL TRANSFORMATION OF BRAIN
TUMOURS
Nature 463, 318–325 (2010)
http://links.ealert.nature.com/ctt?kn=33&m=34590207&r=MTc2ODc4NDI0MAS2&b=2&j=NjYzMTE5NjgS1&mt=1&rt=0
A SYNCHRONIZED QUORUM OF GENETIC CLOCKS
Nature 463, 326–330 (2010)
http://links.ealert.nature.com/ctt?kn=30&m=34590207&r=MTc2ODc4NDI0MAS2&b=2&j=NjYzMTE5NjgS1&mt=1&rt=0
TRANSCRIPTIONAL ROLE OF CYCLIN D1 IN DEVELOPMENT REVEALED BY A
GENETIC–PROTEOMIC SCREEN
Nature 463, 374–378 (2010)
http://links.ealert.nature.com/ctt?kn=32&m=34590207&r=MTc2ODc4NDI0MAS2&b=2&j=NjYzMTE5NjgS1&mt=1&rt=0
------------------------
Signaling News
------------------------
WELCOME TO CELLULAR & MOLECULAR IMMUNOLOGY
http://links.ealert.nature.com/ctt?kn=37&m=34590207&r=MTc2ODc4NDI0MAS2&b=2&j=NjYzMTE5NjgS1&mt=1&rt=0
From January 2010, Nature Publishing Group will co-publish
Cellular & Molecular Immunology, which provides the latest
information and advancements in our understanding of the
immunological response of the host, both in vitro and in vivo,
by featuring basic research and clinical applications. This month's
issue presents a collection of some of the top articles and latest
reviews covering a range of topics including infection and immunity,
transplantation immunology, and tumor immunology.
More news
http://links.ealert.nature.com/ctt?kn=14&m=34590207&r=MTc2ODc4NDI0MAS2&b=2&j=NjYzMTE5NjgS1&mt=1&rt=0
-------------------------
Gateway Updates
-------------------------
NCI-NATURE PATHWAY INTERACTION DATABASE - JANUARY UPDATE
http://links.ealert.nature.com/ctt?kn=21&m=34590207&r=MTc2ODc4NDI0MAS2&b=2&j=NjYzMTE5NjgS1&mt=1&rt=0
The Pathway Interaction Database is a free, high-quality resource of
more than 100 signaling pathways in human cells for biologists and
bioinformaticians to explore, visualize and mine signaling events.
This month's update features C-MYB transcription factor network and
CDC42 signaling events.
Sign up here to receive the monthly update alert for the
NCI-Nature Pathway Interaction Database.
http://links.ealert.nature.com/ctt?kn=11&m=34590207&r=MTc2ODc4NDI0MAS2&b=2&j=NjYzMTE5NjgS1&mt=1&rt=0
======================================================================
Genentech is proud to be a corporate sponsor of the UCSD-Nature
Signaling Gateway.
Genentech is a leading biotechnology company that discovers,
develops, manufactures and commercializes biotherapeutics
for significant unmet medical needs. Fifteen of the currently
approved biotechnology products stem from or are based on
Genentech science. Genentech manufactures and commercializes
ten biotechnology products directly in the United States.
The company has headquarters in South San Francisco, California,
and is traded on the New York Stock Exchange under the symbol DNA.
http://links.ealert.nature.com/ctt?kn=13&m=34590207&r=MTc2ODc4NDI0MAS2&b=2&j=NjYzMTE5NjgS1&mt=1&rt=0
=====================================================================
As a registered user of the Nature Publishing Group web sites, you
were selected to receive this message in the genuine belief that it
would be of interest to you.
If you no longer wish to receive news and announcements from Nature
Publishing Group or wish to unsubscribe from the Signaling Update
email alert please update your online Nature.com account details here:
http://links.ealert.nature.com/ctt?kn=35&m=34590207&r=MTc2ODc4NDI0MAS2&b=2&j=NjYzMTE5NjgS1&mt=1&rt=0
For further technical assistance or any other enquiries, please click here:
http://links.ealert.nature.com/ctt?kn=15&m=34590207&r=MTc2ODc4NDI0MAS2&b=2&j=NjYzMTE5NjgS1&mt=1&rt=0
Nature's world-wide offices:
London . Paris . Munich . New Delhi . Tokyo . Melbourne . San Diego .
San Francisco . Washington . New York . Boston
(c) 2010 Nature Publishing Group
---------------------------------------------------------------------
